| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chaetocin is a fungal secondary metabolite of the epipolythiodioxopiperazine (ETP) class, originally isolated from Chaetomium species. It has potent preclinical anticancer activity through several mechanisms, including inhibition of histone H3K9 methyltransferases such as SUV39H1, reduction of H3K9me3, disruption of thioredoxin/thioredoxin-reductase redox signalling, induction of oxidative stress, inhibition of Hsp90-associated signalling and promotion of apoptosis. Chaetocin can suppress tumour-cell proliferation and stemness and has shown activity in leukemia, glioblastoma, diffuse midline glioma and several solid-tumour models. It can also sensitize cancer cells to apoptosis-inducing agents and radiation. Although frequently described as an SUV39H1 inhibitor, chaetocin is not highly target-selective and its anticancer effects should not be attributed solely to SUV39H1 inhibition. Chaetocin is an experimental fungal metabolite / epigenetic and redox-active anticancer compound, with current therapeutic evidence predominantly preclinical. Chaetocin — a sulfur-rich fungal secondary metabolite of the epipolythiodioxopiperazine (ETP) class originally isolated from Chaetomium species. It is an experimental redox-active and epigenetically active small molecule with potent preclinical anticancer activity. Chaetocin is commonly described as an SUV39H1/KMT1A inhibitor, but this classification is incomplete: it inhibits thioredoxin reductase, produces substantial oxidative stress, covalently perturbs proteins through its reactive disulfide functionality, inhibits multiple histone lysine methyltransferases, disrupts the SUV39H1–HP1 interaction, and can inhibit Hsp90-dependent signaling. It should therefore be classified as a multitarget ETP fungal metabolite / experimental epigenetic-redox anticancer compound rather than as a selective SUV39H1 inhibitor. Primary mechanisms (ranked):
Bioavailability / PK relevance: Human pharmacokinetic parameters, therapeutic plasma concentrations, bioavailability and exposure-response relationships have not been established. Preclinical work indicates unusual intracellular handling related to the intact ETP disulfide groups and cellular redox environment. The highly reactive disulfide pharmacophore, broad protein reactivity and absence of validated human PK are major translational constraints. In-vitro vs systemic exposure relevance: Anticancer potency varies substantially among models, ranging from low-nanomolar effects in some tumor screens to micromolar concentrations in other mechanistic experiments. There is no established human systemic exposure against which these concentrations can be compared. Consequently, even very potent in-vitro observations cannot currently be assumed to represent clinically achievable selective exposure. Normal-cell sparing has been observed in some hematologic and epithelial comparisons, but chaetocin also inhibits normal endothelial-cell proliferation, so tumor selectivity is not established as a general property. Clinical evidence status: Preclinical only. Evidence includes cancer-cell studies, primary patient-derived cells, xenografts and other animal tumor models, with recent work supporting activity in glioblastoma, diffuse midline glioma and cancer stem-cell models. No established human therapeutic trials, randomized clinical evidence or approved adjunct use were identified. Chaetocin remains an experimental research compound and is not an approved anticancer drug. Chaetocin Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: TCGA |
| Type: Antiapoptotic |
| Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response. -One way to estimate Nrf2 induction is through the expression of NQO1. NQO1, the most potent inducer: SFN 0.2 μM, quercetin (2.5 μM), curcumin (2.7 μM), Silymarin (3.6 μM), tamoxifen (5.9 μM), genistein (6.2 μM ), beta-carotene (7.2μM), lutein (17 μM), resveratrol (21 μM), indol-3-carbinol (50 μM), chlorophyll (250 μM), alpha-cryptoxanthin (1.8 mM), and zeaxanthin (2.2 mM) 1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects. 2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death. 3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress -In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies. -Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate. Decreased Nrf2 expression: Skine, Liver, Pancreatic. -Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer - "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1. Nrf2 Inhibitors and Activators Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api - potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue. – In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis. – In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity. – This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming. – Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies. – High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types. – While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression. NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS). -Brusatol: most cited natural inhibitors of Nrf2. -Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent. -Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent . -Oridonin: -Wogonin: although its effects might be cell‑ and dose‑specific. - Withaferin A |
| 7164- | CHA, | Chaetocin induces apoptosis in human melanoma cells through the generation of reactive oxygen species and the intrinsic mitochondrial pathway, and exerts its anti-tumor activity in vivo |
| - | vitro+vivo, | Melanoma, | A375 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:433 Target#:226 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid